Hikma Proves Resilient In 2020 Despite Some Bumpy Launches
Rivals To Advair And Vascepa Suffer From Delays And API Scarcity
Despite turbulence in 2020 from the coronavirus pandemic as well as from difficulties relating to two of its key US generic launches, Hikma has reported solid full-year growth in both sales and profits across its business.
You may also be interested in...
Hikma CEO Siggi Olafsson has outlined the potential future opportunity that the firm sees in the US biosimilars market, in the second part of an exclusive interview with Generics Bulletin.
Four key “moving pieces,” including the next developments for rivals to Advair and Vascepa, will influence the success of Hikma’s US generics business, CEO Siggi Olafsson tells Generics Bulletin in the first part of an exclusive interview.
Hikma has temporarily stopped the roll-out of its rival to Advair Diskus in the US after it filed an amendment to its ANDA over packaging controls.